Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Beuzeboc

Showing results (91-100 of 132) with videos related to

Pageof 14
Sort By:
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|March 19, 2013
[Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy]J Jacob, L Belin, A Gobillion, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 3, 1999
Is primary chemotherapy useful for all patients with primary invasive breast cancer?S M Scholl, P Beuzeboc, A L Harris, et al.
British Journal of Cancer|July 4, 1998
Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90)J Y Pierga, M Jouve, B Asselain, et al.
Breast (Edinburgh, Scotland)|September 30, 2004
Characteristics and outcome of 1755 operable breast cancers in women over 70 years of ageJ-Y Pierga, V Girre, V Laurence, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2001
Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patientsJ Y Pierga, M Robain, M Jouve, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 1, 2009
[Fusion genes and prostate cancer. From discovery to prognosis and therapeutic perspectives]P Beuzeboc, M Soulié, P Richaud, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2000
Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancerM Robain, J Y Pierga, M Jouve, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2010
Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experienceL Staudacher, P H Cottu, V Diéras, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6S M Scholl, A Fourquet, B Asselain, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 1995
Breast tumour response to primary chemotherapy predicts local and distant control as well as survivalS M Scholl, J Y Pierga, B Asselain, et al.
Pageof 14

Showing results (91-100 of 132) with videos related to

Sort By:
Pageof 14
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|March 19, 2013
[Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy]J Jacob, L Belin, A Gobillion, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 3, 1999
Is primary chemotherapy useful for all patients with primary invasive breast cancer?S M Scholl, P Beuzeboc, A L Harris, et al.
British Journal of Cancer|July 4, 1998
Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90)J Y Pierga, M Jouve, B Asselain, et al.
Breast (Edinburgh, Scotland)|September 30, 2004
Characteristics and outcome of 1755 operable breast cancers in women over 70 years of ageJ-Y Pierga, V Girre, V Laurence, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2001
Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patientsJ Y Pierga, M Robain, M Jouve, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|December 1, 2009
[Fusion genes and prostate cancer. From discovery to prognosis and therapeutic perspectives]P Beuzeboc, M Soulié, P Richaud, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2000
Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancerM Robain, J Y Pierga, M Jouve, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2010
Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experienceL Staudacher, P H Cottu, V Diéras, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6S M Scholl, A Fourquet, B Asselain, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 1995
Breast tumour response to primary chemotherapy predicts local and distant control as well as survivalS M Scholl, J Y Pierga, B Asselain, et al.
Pageof 14